PedAM
Pediatric Disease Annotations & Medicines
| Disease | vascular disease |
| Symptom | |diabetes |
| Sentences | 526 |
| PubMedID- 19918016 | The value of low-dose aspirin as primary prevention for cardiovascular disease (cvd) in patients with type 2 diabetes remains to be established. |
| PubMedID- 21330642 | Objective: pulse pressure (pp), an estimate of arterial stiffness, has been shown to be associated with incident cardiovascular disease (cvd) in patients with type 1 diabetes (t1d). |
| PubMedID- 25823004 | After adjustment for clinical covariables (age, crp, diabetes and a history of cardiovascular disease) both stnfrs remained independently associated to outcomes (hr: stnfr1: 1.51, 95% ci: 1.30-1.77; stnfr2: 1.13, 95% ci: 1.06-1.20). |
| PubMedID- 23577222 | Postprandial hyperglycemia may be a risk factor for cardiovascular disease in individuals with diabetes 6. |
| PubMedID- 23031547 | The risk factors for ischemic stroke include aging, hypertension, diabetes, smoking, history of cardiovascular diseases (cvd), atrial fibrillation, and left ventricular hypertrophy. |
| PubMedID- 26473035 | Moreover, microalbuminuria is associated with cardiovascular disease in patients with diabetes mellitus . |
| PubMedID- 26177892 | N = 669inclusion: uncontrolled stage i–ii htn (dbp 90–109 mmhg), background treatment with 1 or 2 anti-htn meds (acei, arb, or diuretic)exclusion: secondary/malignant htn, bradycardia, bmi >35 kg/m2, contraindication to bbs, uncontrolled diabetes, history of mi or cerebrovascular disease, hf, afib or recurrent tachyarrhythmia, severe renal/hepatic diseaserct, db, pbo-controlledneb: 5, 10, or 20 mg/day added to ongoing therapypbo added to ongoing therapyfollow-up at 12 weeksprimary: change in sitting dbpsecondary: change in sitting sbp, response rate (dbp <90 mmhg or decrease in dbp ≥10 mmhg), percent achieving treatment goal (<140/90 mmhg), adverse eventsdbp (ls mean change ± se, mmhg)neb: 5/10/20: −6.6 ± 1.0, −6.8 ± 1.0, −7.9 ± 1.1 (all p < 0.001 vs pbo)pbo: −3.3 ± 1.04sbp (ls mean change ± se, mmhg)neb: 5/10/20: −5.7 ± 1.7 (p < 0.001), −3.7 ± 1.7 (p = 0.015), −6.3 ± 1.7 (p < 0.001)pbo: −0.1 ± 1.7response rate (%)neb: 53.0 (p = 0.028), 60.1 (p = 0.001), 65.1 (p < 0.001)pbo: 41.3bp control (%)neb: 43.2, 41.3, 52.7 (all p ≤ 0.029)pbo: 29.3aes (%)neb (combined doses), 40.2pbo, 38.9 weber et al. |
| PubMedID- 23900314 | Objectives: to provide a systematic and quantitative summary of the association between severe hypoglycaemia and risk of cardiovascular disease in people with type 2 diabetes and to examine the sensitivity of the association to possible uncontrolled confounding by unmeasured comorbid severe illness using a bias analysis. |
| PubMedID- 23417760 | These endothelial alterations contribute to excess cardiovascular disease in diabetes, but may also play a role in the pathogenesis of diabetes, especially type 2. |
| PubMedID- 23604419 | The great burden of cardiovascular disease (cvd) in patients with type 2 diabetes is well known. |
| PubMedID- 20855550 | Additionally, in order to reduce the high risk of cardiovascular disease in people with diabetes (24), a greater use of aspirin (1) has been encouraged. |
| PubMedID- 20522598 | Recent studies have suggested a potential role of the receptor for advanced glycation end products (rage) in the development of vascular disease in individuals with diabetes (1). |
| PubMedID- 25874615 | Pre-diabetes is somewhat predictive of macrovascular diseases, but most of this association seems to be mediated through mets . |
| PubMedID- 20836897 | Multiple and complex pathways promote the deleterious effects of hyperglycemia in diabetes, ultimately leading to micro- and macrovascular disease. |
| PubMedID- 20020220 | Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the framingham heart study. |
| PubMedID- 20653939 | On the contrary, if the patient did not control blood sugar level well and it is highly possible that diabetes was the perpetrator of cardiovascular diseases, then the certifiers could enter diabetes in part i of the death certificate. |
| PubMedID- 26029318 | Further studies addressing the mechanisms responsible for sex differences in the excess risk of cardiovascular diseases associated with diabetes are needed to improve the prevention and management of diabetes in clinical practise. |
| PubMedID- 24800002 | Obesity during childhood has been established to be strongly associated with that in adulthood and also with several chronic diseases such as diabetes, some types of cancer and cardiovascular diseases . |
| PubMedID- 24250240 | However, the action to control cardiovascular disease in diabetes (accord) study revealed an increased cardiovascular mortality rate in intensively treated patients, as well as a minimal benefit to the burden of intensive treatment.3,4 some argue that there is a greater risk than benefit to tight control among geriatric patients.5 the american diabetes association (ada) altered its target glucose goals for the elderly in 2013 to recommend that practitioners individualize therapy.6 yet, how to accomplish this goal in a busy primary care office remains elusive for most practitioners. |
| PubMedID- 26240497 | Several studies have reported that cardiovascular risks factors, including smoking, diabetes, and a history of cardiovascular disease, are also related to hearing loss (578910). |
| PubMedID- 23130125 | Furthermore, we found a positive association between diabetes and other types of vascular disease in the same individuals. |
| PubMedID- 26186882 | Erratum to: favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the fenofibrate intervention and event lowering in diabetes (field) study. |
| PubMedID- 20843975 | Improvements in metabolic control have already been shown to have decreased the frequency of serious complications such as proliferative retinopathy, nephropathy, and cardiovascular disease seen in patients with type 1 diabetes (15,16). |
| PubMedID- 24654672 | Whilst the number of deaths as a result of ketoacidosis or severe hypoglycaemia is lower than for cardiovascular disease in people with type 1 diabetes, these acute metabolic decompensations cause 9–13% of deaths in adults 1,2, with a higher proportion of 20–44% of deaths in children and young adults (excluding ketoacidosis at diagnosis) 1–5. |
| PubMedID- 19889870 | The presence of vascular disease at baseline in patients with diabetes was additive. |
| PubMedID- 22615952 | Model 1: adjusted for age, bmi, current smoking, alcohol intake, exercise, diabetes mellitus, history of cardiovascular disease and history of malignancy. |
| PubMedID- 25609989 | Age-standardized cardiovascular mortality has declined by 20%; however, when associated with diabetes, the mortality due to cardiovascular disease increased by 2% (figure 5). |
| PubMedID- 26318399 | Association between cetp gene polymorphism, insulin resistance and risk of diabetes mellitus in patients with vascular disease. |
| PubMedID- 25526505 | Although the role of glycemic control on microvascular disease in patients with type 2 diabetes was documented in the united kingdom prospective diabetes study24 and other recent studies,4,7 the role of glycemic control for reducing mortality has not yet been established for patients with type 2 diabetes.5–7 although most clinicians agree that effective glycemic control is a desirable intervention for patients with diabetes, the association with increased incidences of hypoglycemia demonstrated in accord, advance and vadt trails has limited the treatment. |
| PubMedID- 22942227 | Primary and secondary prevention of cardiovascular disease in diabetes with aspirin. |
| PubMedID- 23621920 | Helius focuses on three of the major causes of the global burden of disease: cardiovascular disease (including diabetes), mental health (in particular, depressive disorders and substance use disorders), and infectious diseases. |
| PubMedID- 22936794 | At the time of diagnosis of diabetes, patients with established cardiovascular disease had significantly lower mean levels of blood pressure than those without cardiovascular disease (table 1). |
| PubMedID- 22891922 | Postprandial hyperglycemia is a major risk factor for morbidity and mortality from cardiovascular disease in diabetes . |
| PubMedID- 23185656 | The patients with diabetes, dyslipidemia, history of cardiovascular disease (coronary artery disease, congestive heart failure, stroke, transient ischemic attack or intermittent claudication) and carotid artery stenosis were excluded. |
| PubMedID- 20467927 | Results of recent large-scale intervention trials, such as accord, advance, and vadt, seem to undermine the concept that tight glycemic control confers some protection against cardiovascular disease in patients with type 2 diabetes, while maintenance of near-normal glycemic control from earlier stage of the disease and during acute coronary events seems to be more beneficial. |
| PubMedID- 21088641 | All had a history of diabetes mellitus with peripheral vascular disease. |
| PubMedID- 24889279 | Smoking, diabetes, metabolic syndrome, history of cardiovascular disease, increased waist circumference, and elevated pre-treatment ldl-c level were all associated with not reaching ldl-c goals. |
| PubMedID- 20530022 | Management of diabetes mellitus in patients with cardiovascular disease in the bypass angioplasty revascularization investigation 2 diabetes (bari 2d) trial. |
| PubMedID- 21736687 | Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing. |
| PubMedID- 23393213 | Second, the presence of microvascular diseases commonly present in patients with diabetes mellitus may contribute to progressive microvascular ischemia or microembolization that can be readily detectable by highly sensitive ctni assay. |
| PubMedID- 21404226 | Kidney function and mortality in different cardiovascular diseases: relationship with age, sex, diabetes and hypertension. |
| PubMedID- 24252984 | On the other hand no meaningful relationship was detected between diabetes, history of cerebral vascular diseases, peripheral vascular diseases, myocardial infarction, development of pneumonia following surgery, and laboratory levels of sodium, potassium, glucose, and complete blood cell count (cbc) including white blood cells, red blood cells, platelets in the blood-hemoglobin and hematocrits. |
| PubMedID- 25526571 | Key words: vitamin d, diabetes mellitus, deficiency of vitamin d, cancer, cardiovascular diseases, muscle physiology. |
| PubMedID- 23245213 | Background: abnormal circadian blood pressure patterns have been associated with cardiovascular disease in diabetes mellitus. |
| PubMedID- 20798334 | Objective: cerebral microvascular disease associated with type 2 diabetes may exacerbate the effects of aging on cognitive function. |
| PubMedID- 23251156 | The increase in vascular disease in patients with diabetes is thought to be due to the deleterious effects of metabolic abnormalities, such as hyperglycemia, insulin resistance, dyslipidemia, and advanced glycation end products . |
| PubMedID- 22111042 | In addition, hypertension, dyslipidemia and associated diseases, various macrovascular diseases associated with diabetes, and a history of complications from vascular disease were verified through surveys. |
| PubMedID- 20332353 | The excess morbidity and mortality experienced by people with type 2 diabetes is primarily due to increased cardiovascular disease (cvd) risk, and this risk is in turn driven by the triad of hyperglycemia, hypertension, and hyperlipidemia (2). |
| PubMedID- 21569580 | Previous reports have outlined the prognostic importance of undiagnosed diabetes in patients with different cardiovascular diseases . |
| PubMedID- 25214836 | Left ventricular hypertrophy (lvh) and albuminuria are both markers for cardiovascular diseases (cvds) in patients with type 2 diabetes mellitus (t2dm). |